Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging
| Autor: | Benno Weigmann, Claus-Michael Lehr, Maike Windbergs, Eva-Maria Collnot, Hussain Ali, Saeed Ahmad Khan |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Budesonide Fluorescence-lifetime imaging microscopy Stereochemistry Anti-Inflammatory Agents Pharmaceutical Science Nanoparticle 02 engineering and technology Intestinal absorption 03 medical and health sciences Drug Delivery Systems Intestinal mucosa Polylactic Acid-Polyglycolic Acid Copolymer X-Ray Diffraction In vivo medicine Animals Humans Pharmacology (medical) Lactic Acid Intestinal Mucosa Pharmacology Drug Carriers Mice Inbred BALB C Chemistry Organic Chemistry Optical Imaging 021001 nanoscience & nanotechnology Colitis Inflammatory Bowel Diseases Drug Liberation 030104 developmental biology Targeted drug delivery Intestinal Absorption Biophysics Molecular Medicine Nanoparticles 0210 nano-technology Drug carrier Polyglycolic Acid Biotechnology medicine.drug |
| Zdroj: | Pharmaceutical research. 33(5) |
| ISSN: | 1573-904X |
| Popis: | The purpose of this study was to evaluate the specifically targeted efficiency of budesonide loaded PLGA nanoparticles for the treatment of inflammatory bowel disease (IBD). The nanoparticles were prepared by an oil/water (O/W) emulsion evaporation technique. The nanoparticles were characterized for their size, shape and in vitro drug release profile. Solid state characterization was carried out by differential scanning calorimetry (DSC) and X-ray Power diffraction (XPRD). In order to evaluate the targeted efficiency of nanoparticles, a particle localization study in the healthy and in the inflamed colon was determined in vivo. These data were complemented by cryo-sections. Nanoparticles were 200 ± 05 nm in size with a smooth and spherical shape. The encapsulation efficiency was around 85 ± 3.5%, which was find-out by both, direct and indirect methods. Release of budesonide from the nanoparticles showed a biphasic release profile with an initial burst followed by sustained release. XPRD data revealed that the drug in the polymer matrix existed in crystalline state. Nanoparticles accumulation in inflamed tissues was evaluated by in-vivo imaging system and it was found that particles are accumulated in abundance at the site of inflammation when compared to the healthy group. The study demonstrates that the budesonide loaded PLGA nanoparticles are an efficient delivery system for targeted drug delivery to the inflamed intestinal mucosa. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink